Literature DB >> 16701633

The use of the self-management plan system of care in adult asthma.

Shaun Holt1, Matthew Masoli, Richard Beasley.   

Abstract

The development of self-management plans arose as clinicians tried to design better methods by which they could deliver asthma care and reduce the significant mortality and morbidity associated with this disease. The basic principles that resulted have been widely endorsed, and self-management plans are now recommended in the long-term management of adult asthma. Self-management plans essentially focus on the early recognition of unstable or deteriorating asthma, by monitoring peak flow or symptoms. Through the use of written guidelines, patients are then able to determine when it is necessary to adjust therapy or obtain medical assistance. There is now convincing evidence that the use of self-management plans by patients with asthma leads to a marked reduction in morbidity and a reduced requirement for acute medical treatment including hospital admissions. Recent research has also clarified many of the different issues concerning their structure and implementation. In some respects the skill in the use of the asthma self-management plan system of care is the ability to modify the standard plans to meet the particular needs of the individual asthmatic patient, including their preferences.

Entities:  

Year:  2004        PMID: 16701633      PMCID: PMC6750652          DOI: 10.1016/j.pcrj.2003.11.001

Source DB:  PubMed          Journal:  Prim Care Respir J        ISSN: 1471-4418


  7 in total

Review 1.  Personalised asthma action plans for adults with asthma.

Authors:  Timothy L Gatheral; Alison Rushton; David Jw Evans; Caroline A Mulvaney; Nathan R Halcovitch; Gemma Whiteley; Fiona Jr Eccles; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2017-04-10

2.  New therapies and management strategies in the treatment of asthma: patient-focused developments.

Authors:  Joshua Agbetile; Ruth Green
Journal:  J Asthma Allergy       Date:  2010-12-30

3.  The use of β2-agonist therapy before hospital attendance for severe asthma exacerbations: a post-hoc analysis.

Authors:  Mitesh Patel; Janine Pilcher; Robert J Hancox; Davitt Sheahan; Alison Pritchard; Irene Braithwaite; Dominick Shaw; Peter Black; Mark Weatherall; Richard Beasley
Journal:  NPJ Prim Care Respir Med       Date:  2015-01-08       Impact factor: 2.871

4.  Beta-agonist overuse and delay in obtaining medical review in high risk asthma: a secondary analysis of data from a randomised controlled trial.

Authors:  Janine Pilcher; Mitesh Patel; Alison Pritchard; Darmiga Thayabaran; Stefan Ebmeier; Dominick Shaw; Peter Black; Irene Braithwaite; Mark Weatherall; Richard Beasley
Journal:  NPJ Prim Care Respir Med       Date:  2017-05-11       Impact factor: 2.871

5.  Management of Children with Acute Asthma Attack: A RAND/UCLA Appropriateness Approach.

Authors:  Valentina Fainardi; Carlo Caffarelli; Barbara Maria Bergamini; Loretta Biserna; Paolo Bottau; Elena Corinaldesi; Arianna Dondi; Martina Fornaro; Battista Guidi; Francesca Lombardi; Maria Sole Magistrali; Elisabetta Marastoni; Alessandra Piccorossi; Maurizio Poloni; Sylvie Tagliati; Francesca Vaienti; Cristina Venturelli; Giampaolo Ricci; Susanna Esposito
Journal:  Int J Environ Res Public Health       Date:  2021-12-03       Impact factor: 3.390

6.  Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma.

Authors:  James Fingleton; Jo Hardy; Christina Baggott; Janine Pilcher; Andrew Corin; Robert J Hancox; Matire Harwood; Mark Holliday; Helen K Reddel; Philippa Shirtcliffe; Suzanne Snively; Mark Weatherall; Richard Beasley
Journal:  BMJ Open Respir Res       Date:  2017-07-29

7.  Increasing Prevalence and Mortality of Asthma With Age in Korea, 2002-2015: A Nationwide, Population-Based Study.

Authors:  Eunyoung Lee; Anhye Kim; Young Min Ye; Sang Eun Choi; Hae Sim Park
Journal:  Allergy Asthma Immunol Res       Date:  2020-05       Impact factor: 5.764

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.